Assessing the prevalence and impact of HER2-rs1136201 polymorphism in breast cancer development among Bangladeshi women: a case-control study

Abstract

Breast cancer is one of the most malignant diseases in Bangladesh, and it is on the rise among women. The rs1136201 (Ile655Val) single-nucleotide polymorphism (SNP) and the human epidermal growth factor receptor 2 (HER2) gene have been proven to be involved in the development of breast cancer across various populations. The purpose of the study was to determine the relationship between the HER2 rs1136201 polymorphism and the susceptibility of breast cancer in the Bangladesh population among the women of this country on a case-control basis. 236 people, including 112 histopathologically-proven breast cancer patients and 124 age-matched controls, took part in the study. Multivariate logistic regression was used to perform statistical testing under various genetic model assumptions, including additive, dominant, recessive, and overdominant models. The outcomes showed that there was no association with significant results among the HER2 rs1136201 SNP and breast cancer in an additive, dominant, or recessive model (p > 0.05). Nevertheless, an overdominant model was significant (OR = 1.83, 95 % CI = 1.02-3.28; p = 0.041), suggesting that the risk of breast cancer was higher in individuals with AG heterozygote. Considering such an outcome, there may be an overdominance effect of the HER2 polymorphism among the Bangladeshi people. These associations should be confirmed by further research on larger sample sizes and of functional significance to determine their biological roles in the pathogenesis of breast cancer.